Variables | BCS (%) | Mastectomy (%) | Radical Mastectomy (%) | χ2 | P-value |
---|---|---|---|---|---|
Race | |||||
White | 297 (78.0%) | 204 (80.0%) | 467 (76.7%) | ||
Black | 57 (15.0%) | 38 (14.9%) | 95 (15.6%) | 2.12 | 0.714 |
Other | 27 (7.0%) | 13 (5.1%) | 47 (7.7%) | ||
Age | |||||
≤ 35 | 13 (3.4%) | 16 (6.3%) | 38 (6.2%) | ||
35 < age < 60 | 181 (47.5%) | 132 (51.8%) | 318 (52.2%) | 8.373 | 0.079 |
≥ 60 | 187 (49.1%) | 107 (42.0%) | 253 (41.5%) | ||
Grade | |||||
1 | 34 (8.9%) | 20 (7.8%) | 45 (7.4%) | 6.528 | 0.163 |
2 | 173 (45.4%) | 129 (50.6%) | 258 (42.4%) | ||
3–4 | 174 (45.7%) | 106 (41.6%) | 306 (50.2%) | ||
Laterality | |||||
Left | 209 (54.9%) | 130 (51.0%) | 317 (52.1%) | 1.115 | 0.573 |
Right | 172 (45.1%) | 125 (49.0%) | 292 (48.0%) | ||
Marital | |||||
Married | 206 (54.1%) | 138 (54.1%) | 318 (52.2%) | ||
Unmarried | 175 (45.9%) | 117 (45.9%) | 291 (47.8%) | 0.438 | 0.803 |
Ethnic origin | |||||
Spanish-Hispanic-Latino | 43 (11.3%) | 23 (9.0%) | 70 (11.5%) | 1.205 | 0.547 |
Non-Spanish-Hispanic-Latino | 338 (88.7%) | 232 (91.0%) | 539 (88.5%) | ||
Histology | |||||
IDC | 326 (85.6%) | 201 (80.0%) | 49 (77.0%) | 5.163 | 0.076 |
Non-IDC | 55 (14.4%) | 54 (20.0%) | 113 (33.0%) | ||
T stage | |||||
T1 | 91 (23.9%) | 21 (8.2%) | 41 (6.7%) | 158,845 | < 0.001 |
T2 | 22 (58.3%) | 109 (42.7%) | 238 (39.10%) | ||
T3 | 37 (9.7%) | 59 (23.1%) | 146 (24%) | ||
T4 | 31 (8.1%) | 66 (25.9%) | 184 (30.20%) | ||
N stage | |||||
N0 | 126 (33.1%) | 52 (20.4%) | 30 (4.9%) | ||
N1 | 133 (34.9%) | 124 (48.6%) | 206 (33.80%) | 192.317 | < 0.001 |
N2 | 67 (17.6%) | 41 (16.10%) | 153 (25.10%) | ||
N3 | 55 (14.4%) | 38 (14.90%) | 220 (36.10%) | ||
Radiation | |||||
Yes | 22 (60.1%) | 124 (48.6%) | 351 (57.60%) | ||
No | 15 (39.9%) | 131 (51.40%) | 258 (42.40%) | 8.765 | 0.012 |
Chemotherapy | |||||
Yes | 20 (54.9%) | 171 (69.50%) | 423 (67.10%) | ||
No | 17 (45.1%) | 84 (30.50%) | 186 (32.90%) | 22.744 | < 0.001 |
Subtype | |||||
ER + /HER2− | 276 (72.4%) | 177 (69.4%) | 416 (68.3%) | ||
ER + /HER2 + | 54 (14.2%) | 34 (13.3%) | 101 (16.6%) | 6.514 | 0.368 |
HER2 + | 15 (3.9%) | 11 (4.3%) | 35 (5.7%) | ||
TNBC | 36 (9.4%) | 33 (12.9%) | 57 (9.4%) | ||
ER | |||||
Positive | 329 (86.4%) | 207 (81.2%) | 514 (84.4%) | 3.101 | 0.212 |
Negative | 52 (13.6%) | 48 (18.8%) | 95 (15.6%) | ||
PR | |||||
Positive | 281 (73.8%) | 176 (69.0%) | 429 (70.4%) | 1.97 | 0.373 |
Negative | 100 (26.2%) | 79 (31.0%) | 180 (29.6%) | ||
HER2 | |||||
Positive | 69 (18.1%) | 45 (17.6%) | 136 (22.3%) | 3.786 | 0.151 |
Negative | 312 (81.9%) | 210 (82.4%) | 473 (77.7%) |